All In Biotech

Drug Trial Radar · NCT02414165

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Last checked: Nov 20, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 403 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

403

Actual

Start

Nov 30, 2015

Primary completion

May 31, 2019

Study completion Dec 20, 2019

Sponsor

Lead sponsor
Tocagen Inc.Industry
Sponsor type
Industry
First posted
Apr 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation status. A second stratification factor is based on the patient's Karnofsky Performance Score (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices for the control arm in regions, the trial will be stratified by geographical region during the randomization process. Funding Source - FDA OOPD

Conditions

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma

Interventions

  • Toca 511Biological

    Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.

  • Toca FCDrug

    Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets

  • LomustineDrug

  • TemozolomideDrug

  • BevacizumabBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytomaTime frame: 30 December 2019

Locations

67 sites in 4 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • University of California, Irvine

    Irvine, California

  • University of California San Diego

    La Jolla, California

  • University of California, Los Angeles

    Los Angeles, California

  • St. Joseph Hospital

    Orange, California

  • University of California San Francisco

    San Francisco, California

  • Stanford University

    Stanford, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Colorado Neurological Institute

    Englewood, Colorado

  • Associated Neurologists of Southern Connecticut

    Fairfield, Connecticut

  • Yale University/Yale Cancer Center

    New Haven, Connecticut

  • University of Florida McKnight Brain Institute

    Gainesville, Florida

  • University of Miami

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • NorthShore University Health System

    Evanston, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Abbott Northwestern Hospital / Allina Health

    Minneapolis, Minnesota

  • University of Minnesota

    Minneapolis, Minnesota

  • HCA Midwest / Sarah Cannon

    Kansas City, Missouri

  • Washington University St. Louis

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • JFK Medical Center Neuroscience Institute

    Edison, New Jersey

  • John Theurer Cancer Center at Hackensack University

    Hackensack, New Jersey

  • Overlook Medical Center

    Summit, New Jersey

  • North Shore University Hospital

    Lake Success, New York

  • NYU Langone Medical Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Columbia University

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Stony Brook University Hospital

    Stony Brook, New York

  • Cincinnati's Children's Hospital Medical Center

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.